Non-muscle Invasive Bladder Cancer Clinical Trial
— Hydeal CystOfficial title:
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
Prior to performing any study specific procedure (including screening procedures to determine eligibility), a signed consent form will be obtained for each subject. Patients will be enrolled in the study only if they meet all the inclusion criteria and none of the exclusion criteria. Prior to perform any study specific procedure (including screening procedures to determine eligibility), a signed informed consent form will be obtained for each subject. The informed consent form will describe the purpose of the study, the procedures to be followed, and the risk and benefits of participation. The investigator will conduct the informed consent discussion and will check that the subject comprehends the information provided and will answers any questions about the study. Consent will be voluntary and free from coercion. The investigator that will conduct the consent discussion will also sign the informed consent form. A copy of the informed consent form will be given to the subject and the fact that the subject has been consented to the study will be documented in the subject's record. When all the inclusion and exclusion criteria have been addressed and the eligibility of the subject confirmed, the subject may be enrolled in the study. The following activities and/or assessments will be performed during screening, prior the treatment period start: demographic, medications related to the disease or symptoms and cancer history data collection; Urine-colture; randomization; Questionnaires QoL e IPSS. BCG or MMC will be started within 1-2 weeks from randomization (within 4-6 weeks after TURB). BCG or MMC will be administered once a week by intravesical instillation: BCG will be abministered for 6 weeks and MMC for 8 weeks. (induction cycles) Before instillations a physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes. IPSS questionnaire and QoL questionaire will be administered to the patient at week 1, 4 and 6/8 (6 for BCG and 8 for MMC) of treatment. 48 hours after post BCG or MMC intravesical instillation, patients of Arm A will undergo Hydeal Cyst intravesical instillation. BCG patiens will received 6 Hydeal Cyst intravesical instillation; MMC patiens will received 8 Hydeal Cyst intravesical instillation. After 2 weeks from BCG or MMC instillation end, IPSS e QoL questionaires will be administered and a control urino-colture will be executed. After 6 and 12 weeks from instillation therapy end, a control visit will be made. A physical examination will be performed and symptoms evaluated: changes from baseline and abnormalities will be recorded in patient notes. Control cystoscopy and urino-colture will be executed (as for clinical practice) and IPSS and quality of life evaluated.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | June 2026 |
Est. primary completion date | June 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female = 18 years of age - ECOG PS 0-2 - Histologically confirmed diagnosis of non-muscle invasive bladder cancer, naïve and recurrent. - Patients candidate to BCG or MMC intravesical induction therapy. - Transurethral resection (TURB) performed in the last 4 weeks. - IPSS score =10 - Negative urine culture within 2 weeks before T0 - For women who are not postmenopausal (i.e., < 1 year after last menstruation) or surgical-ly sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive de-vice, or barrier method of contraception in conjunction with spermicidal jelly) during the study period - Signed the study informed consent prior to any study specific procedures. - Will and ability to comply with the protocol Exclusion Criteria: - Upper urinary tract urothelial carcinoma (UTUC); bladder diverticula; urethral stenosis; difficult catheterization; reduced bladder compliance; increased bladder compliance; post-voiding residue > 150 ml; - Surgery or invasive procedures planned during the study and interfering with evaluation about efficacy and safety of it. - Female patients with child-bearing potential must not be pregnant or lactating, or not willing to use adequate contraception for the duration of study - Pelvic radiotherapy within 24 weeks prior to the beginning of the study treatment. - Urinary tract infection requiring antibiotics - Have a known hypersensitivity to any substance present in the investigational device. - Neurogenic bladder - Any condition for that, in the opinion of the Investigator, participation would not be in the best interest of the subject. |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale Sant'Orsola - Malpighi | Bologna | |
Italy | Policlinico Ospedali Riuniti - Foggia | Foggia | |
Italy | Azienda Ospedale Università Padova | Padova | |
Italy | Istituto Oncologico Veneto IRCCS | Padova | |
Italy | Ospedali Riuniti Padova Sud | Padova | |
Italy | Ospedale Santa Maria della Misericordia - ASU FC | Udine | |
Italy | Azienda Ospedaliera Universitaria Integrata - Verona | Verona |
Lead Sponsor | Collaborator |
---|---|
Istituto Oncologico Veneto IRCCS | Fidia Farmaceutici s.p.a. |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Lower urinary tract symptoms | Lower urinary tract symptoms will be evaluated by the IPSS questionnaire (score 0-35) at baseline and follow-up visits. Difference from baseline will be calculated at two weeks after the end of induction cycle of intravesical instillation. | From the date of randomization up to 22 weeks | |
Secondary | Recurrence free survival (RFS) | The recurrence free survival (RFS) will be determined as the time from the date of randomization to the date of clinical disease recurrence. Patients without a RFS event at the time of analysis will be censored at the date of last assessment | From the date of randomization up to 22 weeks | |
Secondary | Progression free survival (PFS) | The progression free survival (PFS) will be determined as the time from the date of randomization to the date of clinical disease progression. Patients without a PFS event at the time of analysis will be censored at the date of last assessment | From the date of randomization up to 22 weeks | |
Secondary | Toxicity during the treatment | Toxicity during the treatment will be recorded and graded according to the NCI-Common Terminology Criteria for Adverse Events (CTCAE) v.5. Grade refers to the severity of the adverse event. A grading (severity) scale is provided for each adverse event term. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE. | From the date of randomization up to 22 weeks | |
Secondary | Quality of Life assessment | Quality of Life will be evaluated at randomization (T0), at weeks 4 and 6/8 (T6 for BCG/T8 for MMC) of instillation treatment and during follow-up period (weeks 2, 6 and 12 after instillation treatment end). QoL will be assessed throught the FACT-Bl questionnaire. | From the date of randomization up to 22 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04736394 -
A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients
|
Phase 3 | |
Recruiting |
NCT05951179 -
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04943094 -
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
|
||
Not yet recruiting |
NCT06227065 -
Precise Neoadjuvant Chemoresection of Low Grade NMIBC
|
Phase 2 | |
Completed |
NCT02969109 -
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
|
||
Completed |
NCT01458847 -
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT03914794 -
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
|
Phase 2 | |
Recruiting |
NCT05126472 -
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
|
Phase 1 | |
Recruiting |
NCT04644835 -
Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer
|
N/A | |
Recruiting |
NCT06126796 -
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
|
||
Active, not recruiting |
NCT04100733 -
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
|
N/A | |
Recruiting |
NCT05085990 -
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT03560479 -
A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
Completed |
NCT03081858 -
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04498702 -
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
|
Phase 2 | |
Recruiting |
NCT05337397 -
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
|
||
Active, not recruiting |
NCT04490993 -
Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients
|
Phase 3 | |
Recruiting |
NCT04859751 -
Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT05672615 -
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
|